orphan drug

Sparked by the shock resignation of Sarepta CEO Chris Garabedian; this week I am reviewing the relationship between academia and industry and sharing my perspective as a postdoc working in the midst. My research is focused on a ‘rare’ childhood muscle disorder called Duchenne muscular dystrophy (DMD). Rare disease expertise typically resides in the clinic, academia and […]